PBAC's latest decision on Boceprevir: Recommended with restriction (2012). Considered for treatment, managed by an accredited treatment centre, of chronic hepatitis C genotype 1 infection in combination with peginterferon alfa and ribavirin in patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C.
PBAC outcome
Recommended with restriction
Authority Required | Public Hospital Authority Required (Streamlined)
ICER (AUD/QALY)
$45k/QALY
$15k/QALY–$45k/QALY · across 3 submissions
Submissions
3
first 2011
Submissions
3
2011 → 2012
Eligible population
patients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C
Therapy area
Hepatology
Line of therapy
First-line | Later-line
Comparator
peginterferon alfa with ribavirin
Economic model
CUA
ICER basis
Range aggregates 3 submissions (2011–2012) — not a single base case.
Risk sharing
Risk-sharing arrangement in place — The PBAC recommended that the sponsors of boceprevir and telaprevir rebate to the Government 100 % of the cost of telaprevir and boceprevir above the estimates accepted by the PBAC.
Submission history
Jul 2011: Not recommended · Authority Required — ICER $45k/QALY
Mar 2012: Not recommended · Authority Required — ICER $45k/QALY
Jul 2012: Recommended with restriction · Authority Required | Public Hospital Authority Required (Streamlined) — ICER $45k/QALY